IPM Product Pipeline
Since our inception in 2002, IPM’s pipeline has included products based on antiretrovirals (ARVs) — the same types of drugs that have proven successful in treating HIV/AIDS and preventing mother-to-child transmission in millions of people around the world.
The pipeline of ARV compounds at IPM is a result of our partnerships with pharmaceutical companies. Through royalty-free licensing agreements for seven ARVs or active pharmaceutical ingredients and exclusive worldwide rights for one ARV called dapivirine, we have access to an array of drugs with a variety of mechanisms of action against HIV infection.
The table below provides information on how IPM compounds work and their stage of development at IPM. Our clinical trials page lists IPM clinical trials that are currently under way.
|Compound||License||Mechanism of action||IPM development stage|
|Dapivirine||Janssen R&D Ireland (previously Tibotec)||NNRTI: Reverse transcription||
|DS003 (BMS793)||BMS||gp120: Cell attachment||
|Maraviroc||ViiV Healthcare||CCR5: Cell Attachment||
|Tenofovir||Gilead||NRTI: Reverse transcription||
|DS001 (L167), DS004 (L872), DS005 (L882)||Merck||CCR5: Cell Attachment||
|DS007 (L-644 peptide)||Merck||gp41: Cell fusion||
* Compound is in different stages of development by other organizations
IPM’s active compounds target different steps in viral replication
The candidate microbicides in IPM’s product pipeline target three different steps in the viral replication cycle: attachment, fusion, and reverse transcription.
- Cell attachment: Preventing the virus from attaching to human cells
- Cell fusion: Preventing the virus from entering human cells
- Reverse transcription: Preventing the virus from reproducing inside human cells
Learn more about how microbicides work.